已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors

沙沙利汀 医学 磷酸西他列汀 二甲双胍 肠促胰岛素 低血糖 2型糖尿病 血糖性 内科学 糖化血红素 药理学 二肽基肽酶-4 糖尿病 二肽基肽酶-4抑制剂 利格列汀 内分泌学
作者
Priscilla Hollander,Pamela Kushner
出处
期刊:Postgraduate Medicine [Taylor & Francis]
卷期号:122 (3): 71-80 被引量:58
标识
DOI:10.3810/pgm.2010.05.2144
摘要

AbstractAbstractThe management of type 2 diabetes is designed to reduce disease-related complications and improve long-term outcomes. Achieving glycemic control is a critical component of this process. The selection of drug therapy for reducing blood glucose is made more challenging when patients already have complications or comorbid conditions (eg, high risk for hypoglycemia, obesity, renal impairment). Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation of incretin hormones. By enhancing and prolonging incretin effects, DPP-4 inhibitors stimulate glucose-dependent insulin secretion and also reduce glucagon secretion. This results in improved glycemic control, as reflected by decreases in glycated hemoglobin (HbA1c), fasting plasma glucose, and postprandial plasma glucose. Dipeptidyl peptidase-4 inhibitors also have the potential to improve β-cell function. In randomized clinical trials, the DPP-4 inhibitors saxagliptin and sitagliptin reduced HbA1c by 0.5% to 0.8%, compared with placebo, whether used as monotherapy or in combination with another agent. As initial combination therapy with metformin, saxagliptin and sitagliptin have demonstrated reductions in HbA1c of 2.5% and 1.9%, respectively. The efficacy of the DPP-4 inhibitors was maintained during treatment for up to 2 years, and did not differ in the elderly compared with younger adults. Dipeptidyl peptidase-4 inhibitors offer efficacy similar to other drug classes, and are well tolerated with a lower risk of hypoglycemia, weight-neutral effects, and a low propensity for drug-drug interactions. On the basis of their clinical profiles, the DPP-4 inhibitors are emerging as an attractive option for improving glycemic control in patients with type 2 diabetes. Saxagliptin and sitagliptin are approved for use as initial therapy in combination with metformin, as monotherapy, as well as in combination with metformin, a sulfonylurea, or a thiazolidinedione in patients not adequately controlled by these agents alone.Keywords: incretinDPP-4 inhibitorsaxagliptinsitagliptinglycemic controltolerability
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er的应助被学术超女采纳,获得10
1秒前
sue发布了新的文献求助10
2秒前
3秒前
4秒前
传奇3的应助被没有好果汁吃采纳,获得10
4秒前
帅气恋风发布了新的文献求助10
5秒前
无奈甜瓜完成签到 ,获得积分10
5秒前
Owen的应助被707采纳,获得10
7秒前
我欣永恒发布了新的文献求助10
8秒前
哭泣的犀牛完成签到,获得积分20
9秒前
CipherSage的应助被狗头采纳,获得10
10秒前
风吹麦浪的应助被狗头采纳,获得10
10秒前
田様的应助被狗头采纳,获得10
10秒前
李健的小迷弟的应助被狗头采纳,获得10
10秒前
JamesPei的应助被狗头采纳,获得30
10秒前
默默的电话完成签到 ,获得积分10
11秒前
韦恩完成签到 ,获得积分10
12秒前
今天不跑WB完成签到 ,获得积分10
12秒前
14秒前
安静完成签到 ,获得积分10
17秒前
淡然夏寒发布了新的文献求助10
17秒前
王sohighs完成签到 ,获得积分10
18秒前
18秒前
18秒前
Bin完成签到,获得积分10
20秒前
小马甲的应助被dart1023采纳,获得10
20秒前
小明同学发布了新的文献求助10
20秒前
淡然之槐完成签到 ,获得积分10
21秒前
21秒前
小蘑菇的应助被帅气恋风采纳,获得10
22秒前
23秒前
Azhar发布了新的文献求助10
23秒前
artemis发布了新的文献求助10
25秒前
小二郎的应助被西瓜汁采纳,获得10
27秒前
颜林林发布了新的文献求助10
28秒前
29秒前
炙热梦曼发布了新的文献求助10
32秒前
CLAYmore发布了新的文献求助10
34秒前
科研通AI65的应助被小羊采纳,获得10
35秒前
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189808
求助须知:如何正确求助?哪些是违规求助? 9576988
关于积分的说明 21850976
捐赠科研通 7787775
什么是DOI,文献DOI怎么找? 3435793
关于科研通互助平台的介绍 2559844
邀请新用户注册赠送积分活动 2482687